Connect with us

Health

DR Congo, Angola Conquer Yellow Fever Outbreak

Published

on

By Dipo Olowookere

The Democratic Republic of Congo (DRC) on Wednesday declared the end of the yellow fever outbreak in that country following a similar announcement in Angola December 23, 2016.

This brings an end to the outbreak in both countries after no new confirmed cases were reported from both countries for the past six months.

“We are able to declare the end of one of the largest and most challenging yellow fever outbreak in recent years through the strong and coordinated response by national authorities, local health workers and partners,” said Dr Matshidiso Moeti, the World Health Organization (WHO) Regional Director for Africa, commending the unprecedented and immense response to the outbreak.

The outbreak, which was first detected in Angola in December 2015, had caused 965 confirmed cases of yellow fever across the two countries, with thousands more cases suspected.

The last case detected in Angola was on 23 June 2016 and DRC’s last case was on 12 July the same year.

More than 30 million people were vaccinated in the two countries in emergency vaccination campaigns.

This key part of the response included mop up and preventative campaigns in hard to reach areas up until the end of the year to ensure vaccine protection for as many people in all areas of risk as possible.

This unprecedented response exhausted the global stockpile of yellow fever vaccines several times.

More than 41 000 volunteers and 8000 vaccination teams with more than 56 NGO partners were involved in the mass immunization campaigns.

The vaccines used came from a global stockpile co-managed by Médecins Sans Frontières (MSF), International Federation of the Red Cross and Red Crescent Societies (IFRC), UNICEF and WHO.

In the first 6 months of 2016 alone, the partners delivered more than 19 million doses of the vaccine – three times the 6 million doses usually put aside for an outbreak. Gavi, the Vaccine Alliance financed a significant proportion of the vaccines.

The first cases in this outbreak were identified on 5 December 2015 in Viana, Luanda Province, Angola. The outbreak spread to the entire country and to neighbouring country Democratic Republic of the Congo, where local transmission was established in March 2016.

From the start of the outbreak, Angola reported a total of 4306 suspected cases and 376 deaths, of which 884 cases and 121 deaths were laboratory confirmed.

In this outbreak, DRC has reported 2987 suspected cases, with 81 laboratory confirmed cases and 16 deaths.

One of the major achievements of the response to this outbreak was the introduction of an innovative dose-sparing strategy using one fifth of a regular dose of the yellow fever vaccine – a technique approved by WHO’s global vaccine expert group to protect as many people as possible from the immediate threat of a major urban outbreak.

WHO supported the Ministry of Health in DRC to vaccinate 10.7 million people in the city of Kinshasa using this dose-sparing strategy as a short-term measure that will provide immunity against yellow fever for at least 12 months and likely longer.

In addition to supporting mass vaccination campaigns, WHO and partners continue to provide support to Angola and DRC to strengthen disease surveillance, to control the spread of mosquitoes and engage communities so that they can protect themselves.

Climate change, the increased mobility of people within and across borders from rural to densely populated urban areas, and the resurgence of the Aedes aegypti mosquito are increasing the risk of yellow fever epidemics.

“Yellow Fever outbreaks like the one in Angola and the DRC could become more frequent in many parts of the world unless coordinated measures are taken to protect people most at risk. Therefore we need to implement a strong preventive approach to vaccinate the population at risk across the region,” said Dr Ibrahima Socé Fall, WHO Regional Emergency Director.

In response, a broad coalition of partners including WHO recently developed a new strategy calling for the ‘Elimination of Yellow fever Epidemics’ (EYE) to strengthen global action and integrate lessons learnt from the outbreak in Angola and DRC.

Key components of the EYE strategy include measures to ensure people are vaccinated before an outbreak strikes, increase the number of global vaccine stocks for outbreak response and support for greater preparedness in the most at-risk countries.

The Organization’s response to the outbreak has been possible thanks to financial support from the Angolan, German and Japanese Governments, Gavi, the Vaccine Alliance, BioManguinhos, the Central Emergency Response Fund (CERF), the WHO International Coordination Group (ICG) Revolving Fund, USAID and the Contingency Fund for Emergencies.

Dipo Olowookere is a journalist based in Nigeria that has passion for reporting business news stories. At his leisure time, he watches football and supports 3SC of Ibadan. Mr Olowookere can be reached via [email protected]

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

WHX in Lagos 2026: Nigeria Open for Healthcare Investment—FG

Published

on

WHX in Lagos 2026

By Modupe Gbadeyanka

The federal government has urged global investors and innovators to tap into the Nigerian healthcare ecosystem, which is projected to grow by 7.1 per cent, reaching a market value of $161.7 million by 2027.

This advice was given by the Minister of State for Health and Social Welfare, Mr Isiaq Salako, at the opening of the World Health Expo (WHX in Lagos 2026), formerly known as Medic West Africa, on Tuesday in Lagos.

The broader West African market is expected to reach more than $11 billion, providing investors with an opportunity to get a good return on investment.

“Nigeria is open for healthcare investment. We want platforms like WHX in Lagos to serve as a critical conduit for translating this investment ambition into tangible technology access for our hospitals and patients,” the Minister, who declared the event open on behalf of President Bola Tinubu, said.

He praised the organisers of the expo, which welcomed over 8,000 healthcare professionals and 500 exhibitors spanning 40 countries, for growing the programme into a vital catalyst for West African healthcare transformation.

Addressing the stark reality that between 85 per cent and 99 per cent of medical equipment and in vitro diagnostics in West Africa are currently imported, Mr Salako outlined aggressive federal interventions designed to dismantle supply chain vulnerabilities and skyrocket local manufacturing capabilities.

He also spotlighted key presidential directives, including the Presidential Initiative to Unlock Healthcare Value Chains (PVAC) and the Presidential Executive Order for the Pharmaceutical and Allied Sectors, both engineered to catalyse health security, drive economic growth, and generate employment through strategic private-sector collaborations and Public-Private Partnerships (PPPs).

“Our commitment to improving access to modern equipment and technologies in hospitals is backed by concrete action. The government has inaugurated the $1.2 billion Sector-Wide Approach (SWAP) initiative, a comprehensive overhaul addressing financing, workforce development, and infrastructure.

“Furthermore, for the 2025 fiscal year, the Federal Government committed N402 billion specifically for health sector infrastructure investment,” he stated, also highlighting an expansive health infrastructure upgrade program in partnership with the Nigeria Sovereign Investment Authority (NSIA).

According to him, this phased initiative is actively delivering oncology and nuclear medicine centres across six tertiary hospitals, alongside establishing 22 modern medical diagnostic centres, seven cardiac catheterisation laboratories, and expanded radiology and clinical pathology capabilities distributed across Nigeria’s six geopolitical zones.

Also speaking, the chief executive of EHA Clinics, Dr Ifunanya Ilodibe, stressed the urgent need to support and unify fragmented growth within the healthcare system, noting that WHX serves as the precise ecosystem platform required to bring together policymakers, clinicians, and investors to move actionable strategies forward.

Also, the President of the Healthcare Federation of Nigeria (HFN) and Country Director of PharmAccess, Njide Ndili, said, “HFN bridges the gaps in health financing, opening up critical connections to achieve true health sovereignty,” praising Africa CDC’s historical intervention, particularly during the Ebola crisis and urged participants to utilise the WHX exhibition floor to forge collaborations capable of scaling locally produced medical equipment.

The Lagos State Commissioner for Health, Mr Akin Abayomi, on his part, highlighted the enforcement of the National Health Insurance Authority (NHIA) Act in Lagos State as a landmark regulatory milestone. The Act mandates health insurance for all residents, structuring the financial environment to guarantee medical protection across various socioeconomic levels.

Delivering the keynote address, the Special Regional Representative of the Director General of the Africa CDC Western Regional Coordinating Centre, Prof. Aliko Ahmed, called on leaders in geopolitical positions to enact liberating trade policies aligned with the African Continental Free Trade Area (AfCFTA) to shape the continental agenda, emphasising that the Africa CDC will fiercely prioritise building trust in locally manufactured healthcare products.

WHX in Lagos 2026 runs for three days, featuring accredited forums, cutting-edge product showcases, and high-level networking tracks designed to translate billions in public and private investment into immediate technology access for hospitals and patients.

Continue Reading

Health

Euracare Secures Court Order Halting Inquest into Chimamanda Son’s Death

Published

on

Euracare

By Adedapo Adesanya

The coroner’s inquest into the death of 21-month-old Nkanu Adichie-Esege, son of renowned author Chimamanda Ngozi Adichie, suffered a major setback on Wednesday after Euracare Multi-Specialist Hospital informed the coroner’s court that it had obtained an order of the Lagos State High Court staying further proceedings in the probe.

The matter came before Coroner Magistrate Atinuke Adetunji at Court 9, Igbosere Magisterial District, Yaba, Lagos, and was scheduled for the commencement of witness’ testimony.

Counsel to Euracare Multi-Specialist Hospital, Professor Taiwo Osipitan (SAN), told the court that the hospital had initiated judicial review proceedings challenging, among other issues, the jurisdiction of the Coroner’s Court to conduct the inquest in the absence of the deceased’s body.

He disclosed that the High Court had granted leave for the judicial review application and ordered that the leave operate as a stay of proceedings pending the determination of the suit.

The senior advocate also informed the court that although the Lagos State Attorney-General’s Office denied seeing the originating processes from the High Court, proof of service was available.

Responding on behalf of the family, Mr Kemi Pinheiro (SAN) confirmed receipt of both the originating processes and the High Court order.

While acknowledging the obligation of all parties to comply with court orders, he informed the coroner that the family had already filed four witness statements on oath, including that of Dr Ivara Esege, as well as statements from independent medical experts from Nigeria and the United States, who are expected to testify at the inquest.

Mr Pinheiro urged the court not to adjourn the matter indefinitely, but to a definite date after the court vacation to enable parties to report on developments in the High Court proceedings.

He also highlighted the need for transparency and public confidence in the fact-finding process, saying, “He who is innocent does not fear an open inquest.”

Counsel representing Atlantis Paediatric Hospital supported the request for a definite adjournment rather than an indefinite postponement.

Following submissions by counsel, the Coroner adjourned the matter until October 8, 2026, for a report on the status of the High Court proceedings.

Continue Reading

Health

Gavi Promises $50m for Bundibugyo Ebolavirus Vaccines

Published

on

Bundibugyo Ebolavirus Vaccines

By Modupe Gbadeyanka

About $50 million has been promised by Gavi, the Vaccine Alliance, through its First Response Fund (FRF), to support the response to the ongoing Bundibugyo ebolavirus outbreak.

A statement from the organisation made available to Business Post on Monday said up to $40 million would be available to enable accelerated access to investigational doses and, eventually, approved vaccines, while a further $10 million would support outbreak response and protection of routine immunisation services in impacted countries.

“We need to act now to ensure that, once one or more vaccine candidates are ready, manufacturers are in a position to start producing doses at scale,” the chief executive of Gavi, Dr Sania Nishtar, was quoted as saying.

“Leveraging this allocation, Gavi will work closely with CEPI and partners to design the right incentives to achieve this goal, exploring all options, including potential Advance Purchase Commitments.

“This effort, alongside ensuring emergency funds are on hand to support outbreak response and protect routine immunisation services in the communities impacted, is exactly what our First Response Fund was designed for,” Dr Nishtar added.

The First Response Fund is the only globally approved mechanism that allows “at-risk” financing for scaled-up production of vaccines under development. This means Gavi is able to make vital early investments even when development outcomes are uncertain.

The $40 million in immediate surge financing that has been approved today will enable manufacturers of the leading candidates of a vaccine against the Bundibugyo virus to directly commit to high-capacity manufacturing.

This, in turn, will ensure that, as soon as clinical trials demonstrate positive outcomes, investigational vaccine doses could be deployed rapidly to support outbreak response.

Looking to the longer-term, Gavi will also provide incentives for manufacturers to adopt the fastest pathways towards WHO Emergency Use Listing (EUL) and/or WHO Prequalification (PQ), which are critical global approvals that will enable the rapid use of these vaccines in future emergencies.

In the coming weeks, Gavi will finalise the design of a financial mechanism that leverages the $40 million FRF allocation to achieve these vaccine access goals, in close partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) as well as WHO, Africa Centres for Disease Control and Prevention (Africa CDC) and UNICEF.

The final design will take into account the characteristics of individual vaccine candidates and the needs of their manufacturers and may include mechanisms such as Advance Purchase Commitments. Work will also be undertaken to ensure successful candidates from African-based vaccine manufacturers can benefit from accelerated support through Gavi’s African Vaccine Manufacturing Accelerator (AVMA) initiative.

In addition to these investments, Gavi will also immediately release US$ 10 million to support countries and partners with outbreak response.

This funding will support implementation of national outbreak response plans, including targeted investments to protect routine immunisation, protect health care workers and ensure readiness for future vaccines. Gavi will work closely with countries, partners including Africa CDC, WHO, UNICEF, World Bank, and donors to ensure these investments complement other efforts.

Continue Reading

Trending